Get the Stockscreener App
78.69
1.19%
-0.965
Revolution Medicines Inc stock is traded at $78.69, with a volume of 996.06K.
It is down -1.19% in the last 24 hours and up +4.50% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$79.65
Open:
$80.29
24h Volume:
996.06K
Relative Volume:
0.46
Market Cap:
$15.21B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-21.50
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
-2.54%
1M Performance:
+4.50%
6M Performance:
+111.62%
1Y Performance:
+78.87%
1-Day Range:
$77.86
$80.47
1-Week Range:
$77.86
$80.92
52-Week Range:
$29.17
$81.97
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
78.68 | 15.40B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.65 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.54 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.14 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
841.62 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.45 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-03-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-16-25 | Resumed | Stifel | Buy |
| Sep-12-25 | Resumed | Raymond James | Strong Buy |
| Sep-05-25 | Initiated | Truist | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Aug-15-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Free Popular Stock Picks Selection - earlytimes.in
Harbor Capital Advisors Inc. Has $1.01 Million Position in Revolution Medicines, Inc. $RVMD - MarketBeat
What sentiment indicators say about Revolution Medicines Inc. stockLong-Term Investment Plans & Access Free Risk Analysis Before You Invest - Bollywood Helpline
Revolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Extending Long-Term Upside Potential - TipRanks
Revolution Medicines stock hits all-time high at 81.49 USD By Investing.com - Investing.com Nigeria
Understanding Momentum Shifts in (RVMD) - news.stocktradersdaily.com
Revolution Medicines (NASDAQ:RVMD) Hits New 52-Week HighHere's What Happened - MarketBeat
Revolution Medicines stock hits all-time high at 81.49 USD - Investing.com
How resilient is Revolution Medicines Inc. stock in market downturns2025 Price Targets & Long-Term Growth Stock Strategies - ulpravda.ru
Trend Review: Will Revolution Medicines Inc. stock deliver long term returnsMarket Risk Report & Scalable Portfolio Growth Methods - ulpravda.ru
Why ETFs are accumulating Revolution Medicines Inc. (42Z) stockQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - DonanımHaber
How Revolution Medicines Inc. stock valuations compare to rivalsWeekly Profit Recap & Capital Protection Trading Alerts - DonanımHaber
Is Revolution Medicines Inc. stock positioned for digital transformationJuly 2025 Earnings & Detailed Earnings Play Alerts - DonanımHaber
Is Revolution Medicines Inc. stock positioned well for digital economyMarket Performance Report & Stepwise Trade Execution Plans - DonanımHaber
Can Revolution Medicines Inc. stock weather global recession - DonanımHaber
Why Revolution Medicines Inc. Equity Warrant stock could outperform in 2025Earnings Growth Report & Low Risk High Reward Ideas - Улправда
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 15,394 Shares of Stock - MarketBeat
Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 3,104 Shares - MarketBeat
Revolution Medicines Insider Sold Shares Worth $1,182,526, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines (RVMD) General Counsel reports Form 4 stock sale - Stock Titan
Revolution Medicines (RVMD) CEO Goldsmith discloses 15,394-share tax-related sale - Stock Titan
[Form 4] Revolution Medicines, Inc. Insider Trading Activity - Stock Titan
Revolution Medicines (RVMD) COO reports 4,847-share sale under Rule 10b5-1 plan - Stock Titan
Revolution Medicines (RVMD) CFO reports 3,104-share sale under 10b5-1 plan - Stock Titan
Revolution Medicines Says First Patient Randomized in Phase 3 Pancreatic Cancer Trial - marketscreener.com
Revolution Medicines (RVMD) Launches Key Phase 3 Trial for Pancr - GuruFocus
Revolution Medicines randomizes first patient in Rasolute-304 trial - marketscreener.com
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy - The Manila Times
Breakouts Watch: How Revolution Medicines Inc. Equity Warrant stock responds to policy changesJuly 2025 Macro Moves & Real-Time Volume Analysis - Улправда
Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells $372,346.54 in Stock - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by Analysts - MarketBeat
HRT Financial LP Increases Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Holocene Advisors LP Lowers Holdings in Revolution Medicines, Inc. $RVMD - MarketBeat
Bellevue Group AG Purchases 205,000 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Officer Kelsey Files To Sell 5,296 Of Revolution Medicines Inc [RVMD] - TradingView — Track All Markets
CFO Anders Files To Sell 3,017 Of Revolution Medicines Inc [RVMD] - TradingView — Track All Markets
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics - biocentury.com
Avoiding Lag: Real-Time Signals in (RVMD) Movement - news.stocktradersdaily.com
FDA Breakthrough Status For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD) - Yahoo Finance
Delphia Therapeutics Appoints Steve Kelsey, M.D., To Board - citybiz
Revolution Medicines (NASDAQ:RVMD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Revolution Medicines, Inc. $RVMD Shares Sold by Hood River Capital Management LLC - MarketBeat
New York State Common Retirement Fund Grows Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) up 27.9% since last earnings report: Can it continue? - MSN
Norges Bank Invests $62.58 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
State Board of Administration of Florida Retirement System Acquires 30,128 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue? - sharewise.com
Will Revolution Medicines Inc. Equity Warrant stock split attract more investors2025 Retail Activity & Weekly High Momentum Picks - Newser
Why Revolution Medicines Inc. Equity Warrant stock is favored by pension fundsJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - Newser
Russell Investments Group Ltd. Sells 86,034 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Why hedge funds are buying Revolution Medicines Inc. Equity Warrant stock2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Revolution Medicines Inc Stock (RVMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GOLDSMITH MARK A | See Remarks |
Dec 16 '25 |
Sale |
76.82 |
15,394 |
1,182,526 |
232,469 |
| Kelsey Stephen Michael | See Remarks |
Dec 16 '25 |
Sale |
76.82 |
5,447 |
418,423 |
278,600 |
| Horn Margaret A | Chief Operating Officer |
Dec 16 '25 |
Sale |
76.82 |
4,847 |
372,333 |
141,053 |
| Anders Jack | Chief Financial Officer |
Dec 16 '25 |
Sale |
77.09 |
3,104 |
239,289 |
108,065 |
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):